Weight Loss Medications in the Treatment of Obesity and Hypertension
Purpose of Review
Weight loss is strongly associated with improvement in blood pressure; however, the mechanism of weight loss can impact the magnitude and sustainability of blood pressure reduction.
Five drugs—orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion—are currently approved for weight loss therapy in the USA. Naltrexone/bupropion results in an increase in in-office and ambulatory blood pressure compared to placebo. Other therapies are associated with modest lowering of blood pressure, and are generally well-tolerated; nonetheless, evidence is limited regarding their effect on blood pressure, particularly longitudinally, in individuals with hypertension.
Although weight loss medications can be an effective adjunct to lifestyle modifications in individuals with obesity, there is limited evidence regarding their benefit with regard to blood pressure. Future studies evaluating the effectiveness of weight loss medications should include careful assessment of their short- and long-term impact on blood pressure in individuals with hypertension.
KeywordsObesity Hypertension Blood pressure Weight loss Weight loss medication Weight loss pharmacotherapy
The authors thank Katelyn Daigle for editorial assistance in preparing the manuscript.
Compliance with Ethical Standards
Conflict of Interest
Dr. Cohen has no financial conflicts of interest to disclose. Dr. Gadde is an advisor to AstraZeneca with payments made to his employer, Pennington Biomedical Research Center; has received research support from AstraZeneca, BioKier, and National Institutes of Health (NIH); and has received speaking honoraria from the American Diabetes Association.
Human and Animal Rights and Informed Consent
This review article does not contain any studies with human subjects or animals performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•• The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27. https://doi.org/10.1056/NEJMoa1614362. This study analyzed data from >68 million persons to assess trends in overweight/obesity between 1980 and 2015. Additionally, the investigators quantified the burden of disease related to BMI, according to age, sex, cause, and BMI in 195 countries. CrossRefGoogle Scholar
- 4.Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085–95. https://doi.org/10.1016/S0140-6736(11)60105-0.CrossRefPubMedGoogle Scholar
- 11.Fonseca-Reyes S, de Alba-Garcia JG, Parra-Carrillo JZ, Paczka-Zapata JA. Effect of standard cuff on blood pressure readings in patients with obese arms. How frequent are arms of a ‘large circumference’? Blood Press Monit. 2003;8:101–6. https://doi.org/10.1097/01.mbp.0000085763.28312.03.CrossRefPubMedGoogle Scholar
- 12.Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension. 2004;44:127–33. https://doi.org/10.1161/01.HYP.0000137982.10191.0a.CrossRefPubMedGoogle Scholar
- 15.Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, et al. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015;65:45–53. https://doi.org/10.1161/HYPERTENSIONAHA.114.03936.CrossRefPubMedGoogle Scholar
- 17.• Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. The adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132:2134–45. https://doi.org/10.1161/CIRCULATIONAHA.115.018226. This in vitro study demonstrated that leptin acts directly on adrenal glomerulus cells to stimulate aldosterone production and pro-fibrotic cardiac markers. CrossRefPubMedGoogle Scholar
- 20.Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25:532–8. https://doi.org/10.1038/jhh.2010.95.CrossRefPubMedGoogle Scholar
- 26.Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005;46:1316–20. https://doi.org/10.1161/01.HYP.0000190819.07663.da.CrossRefPubMedGoogle Scholar
- 28.Raij L, Egan BM, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. J Clin Hypertens (Greenwich). 2011;13:731–8. https://doi.org/10.1111/j.1751-7176.2011.00499.x.CrossRefGoogle Scholar
- 29.Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens. 2009;27:1493–501. https://doi.org/10.1097/HJH.0b013e32832be593.CrossRefPubMedGoogle Scholar
- 31.Engeli S, May M, Nussberger J, Danser AHJ, Dole WP, Prescott MF, et al. Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. J Am Soc Hypertens. 2017;11(8):488–97. https://doi.org/10.1016/j.jash.2017.06.002.CrossRefPubMedGoogle Scholar
- 32.Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens. 2013;31:393–403. https://doi.org/10.1097/HJH.0b013e32835b6c02.CrossRefPubMedGoogle Scholar
- 34.Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84. https://doi.org/10.1161/01.HYP.0000094221.86888.AE.CrossRefPubMedGoogle Scholar
- 35.Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension. 2009;54:756–62. https://doi.org/10.1161/HYPERTENSIONAHA.109.135178.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. JAMA. 2018;319:266–78. https://doi.org/10.1001/jama.2017.20813.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension). Circulation. 2018;137:1132–42. https://doi.org/10.1161/CIRCULATIONAHA.117.032130.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Jakobsen GS, Smastuen MC, Sandbu R, Nordstrand N, Hofso D, Lindberg M, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. JAMA. 2018;319:291–301. https://doi.org/10.1001/jama.2017.21055.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–62. https://doi.org/10.1161/01.HYP.0000154361.47683.d3.CrossRefPubMedGoogle Scholar
- 44.Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Phys. 1991;261:R1418–23.Google Scholar
- 45.Mastellos N, Gunn LH, Felix LM, Car J, Majeed A. Transtheoretical model stages of change for dietary and physical exercise modification in weight loss management for overweight and obese adults. Cochrane Database Syst Rev. 2014;2:CD008066. https://doi.org/10.1002/14651858.CD008066.pub3.CrossRefGoogle Scholar
- 46.Lin JS, O’Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral counseling to promote a healthy lifestyle for cardiovascular disease prevention in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;161:568–78.CrossRefGoogle Scholar
- 48.•• Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med. 2014;370:2265–75. https://doi.org/10.1056/NEJMoa1306187. This RCT of patients with obesity and moderate to severe sleep apnea evaluated the effects of weight loss, CPAP, or both on several intermediate markers of cardiovascular risk. CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Schwingshackl L, Chaimani A, Schwedhelm C, Toledo E, Punsch M, Hoffmann G, et al. Comparative effects of different dietary approaches on blood pressure in hypertensive and pre-hypertensive patients: a systematic review and network meta-analysis. Crit Rev Food Sci Nutr. 2018:1–14. https://doi.org/10.1080/10408398.2018.1463967.
- 51.Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10. https://doi.org/10.1056/NEJM200101043440101.CrossRefPubMedGoogle Scholar
- 52.Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126–35. https://doi.org/10.1001/archinternmed.2009.470.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24:215–33. https://doi.org/10.1097/01.hjh.0000199800.72563.26.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.•• Gadde KM, Martin CK, Berthoud H-R, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71:69–84. https://doi.org/10.1016/j.jacc.2017.11.011. This an in-depth recent review of the pathophysiology, pathways from adiposity-associated major risk factors to development of heart failure, and a comprehensive review of interventions for obesity. CrossRefPubMedGoogle Scholar
- 67.Adipex-P (phentermine hydrochloride) tablets prescribing information. Horsham: Teva Pharmaceuticals. 2017.Google Scholar
- 69.LeBlanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434–47. https://doi.org/10.7326/0003-4819-155-7-201110040-00006.CrossRefPubMedGoogle Scholar
- 71.Khera R, Murad MM, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34. https://doi.org/10.1001/jama.2016.7602.CrossRefPubMedPubMedCentralGoogle Scholar
- 72.Sahebkar A, Simental-Mendia LE, Kovanen PT, Pedone C, Simental-Mendia M, Cicero AFG. Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials. J Am Soc Hypertens. 2018;12:80–96. https://doi.org/10.1016/j.jash.2017.12.002.CrossRefPubMedGoogle Scholar
- 73.• Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. https://wayback.archive-it.org/7993/20170403223906/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/default.htm. Accessed 10 Dec 2018. FDA briefing documents drugs approved for weight management since 2010 are available via this link.
- 74.Food and Drug Administration. Guidance for industry: developing products for weight management, draft guidance, revision 1. Center for Drug Evaluation and Research (CDER). Rockville: FDA; 2007. https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 10 Dec 2018Google Scholar
- 75.Orexigen Therapeutics. Contrave (naltrexone SR/bupropion SR combination), NDA 200063. Advisory committee briefing document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 2010 December 7. https://wayback.archive-it.org/7993/20170405220555/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235671.pdf. Accessed 10 Dec 2018.
- 76.Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990–1004. https://doi.org/10.1001/jama.2016.1558.CrossRefPubMedGoogle Scholar
- 77.• Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52. https://doi.org/10.1016/S0140-6736(11)60205-5. This is the largest RCT of the most effective of the currently available weight loss drugs. CrossRefPubMedGoogle Scholar
- 78.Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2016:CD007654. https://doi.org/10.1002/14651858.CD007654.pub4.
- 81.Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023. https://doi.org/10.1016/j.jacc.2013.11.004.CrossRefPubMedGoogle Scholar
- 88.Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693–700. https://doi.org/10.1161/HYPERTENSIONAHA.115.06981.CrossRefPubMedGoogle Scholar
- 90.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–324. https://doi.org/10.1161/HYP.0000000000000066.CrossRefGoogle Scholar